Diligence memo · auto-generated · as of July 2, 2026
Slingshot Biosciences, Inc.
Slingshot Biosciences, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Slingshot Biosciences, Inc. operates in Biotech / Pharma, based in EMERYVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Slingshot Biosciences, Inc. has raised $49M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $26M on 2023-01-24.
Most recent recorded round closed around 2023-01-24.
Valuation (modeled)modeled
Provath models Slingshot Biosciences, Inc. at approximately $335M (range $54M–$789M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.27× the median modeled value of Series B Biotech / Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era. Within the normal band (127% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 3.4 yr ago; this sector typically re-raises about every 15 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 2.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 89% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: Carbon Biosciences, Inc., Nueva Bio LLC, Telesis Bio Inc., Turn Biotechnologies, Inc., Surf Bio, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.